Develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders
NovImmune has raised €192M across 7 funding rounds from 7 investors, most recently a Series D+ round in Jan 2016. Based in Plan-les-Ouates, Switzerland; founded 1998; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2016-01-01 | Series D+ | €27M | — | View deal → |
| 2014-02-01 | Series D+ | €49M | Rosetta Capital | View deal → |
| 2012-10-01 | Grant | €6.0M | — | View deal → |
| 2010-12-01 | Series D+ | €17M | BZ Bank | View deal → |
| 2009-05-01 | Series C | €41M | Aravis Ventures,BZ Bank,LODH Immunology Fund,Novartis Venture Fund,Pictet,Varuma | View deal → |
| 2006-06-01 | Series B | €36M | Aravis Ventures,LODH Immunology Fund,Novartis Venture Fund,Pictet | View deal → |
| 2000-05-01 | Series A | €15M | LODH Immunology Fund,Novartis Venture Fund | View deal → |
